Drug intelligence / Profile preview

Atezolizumab + Cisplatin

Development stage: Unknown
Lead developer: Roche
Modality: Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration: Intravenous

Overview

Atezolizumab + cisplatin is a combination therapy used in cancer treatment, particularly for lung cancer. This combination pairs atezolizumab, an immune checkpoint inhibitor, with cisplatin, a platinum-based chemotherapy agent. When combined, these medications provide a dual approach to fighting cancer - direct cytotoxic effects from cisplatin and immune system activation from atezolizumab.

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on Atezolizumab + Cisplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atezolizumab + Cisplatin.

Explore the full profile